Memory Pharmaceuticals Company Description
If mem'ries don't light the corners of your mind, Memory Pharmaceuticals tried to help. Working from research conducted by Nobel Prize-winning scientist (and company founder) Eric Kandel, the pharmaceutical firm aimed to create new therapies for memory loss and cognition difficulties stemming from age or conditions such as Alzheimer's and Parkinson's diseases, schizophrenia, and depression. By targeting cell pathways linked to memory formation, the firm hoped to prevent the memory loss that makes many central nervous system (CNS) afflictions so debilitating. Memory Pharmaceuticals was acquired by top Swiss drug firm Roche Holding in early 2009
View the Comprehensive Company Description for Memory Pharmaceuticals
The Company Description provides a historical perspective of Memory Pharmaceuticals's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Memory Pharmaceuticals's evolution in the marketplace.
